Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil VSports app下载. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2009 Apr 9;52(7):1864-72.
doi: 10.1021/jm801343r.

Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice

Ramesh Gujjar  1 , Alka Marwaha, Farah El Mazouni, John White, Karen L White, Sharon Creason, David M Shackleford, Jeffrey Baldwin, William N Charman, Frederick S Buckner, Susan Charman, Pradipsinh K Rathod, Margaret A Phillips
Affiliations

Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice

Ramesh Gujjar et al. J Med Chem. .

Abstract

Plasmodium falciparum causes 1-2 million deaths annually. Yet current drug therapies are compromised by resistance. We previously described potent and selective triazolopyrimidine-based inhibitors of P. falciparum dihydroorotate dehydrogenase (PfDHODH) that inhibited parasite growth in vitro; however, they showed no activity in vivo. Here we show that lack of efficacy against P. berghei in mice resulted from a combination of poor plasma exposure and reduced potency against P. berghei DHODH. For compounds containing naphthyl (DSM1) or anthracenyl (DSM2), plasma exposure was reduced upon repeated dosing. Phenyl-substituted triazolopyrimidines were synthesized leading to identification of analogs with low predicted metabolism in human liver microsomes and which showed prolonged exposure in mice VSports手机版. Compound 21 (DSM74), containing p-trifluoromethylphenyl, suppressed growth of P. berghei in mice after oral administration. This study provides the first proof of concept that DHODH inhibitors can suppress Plasmodium growth in vivo, validating DHODH as a new target for antimalarial chemotherapy. .

PubMed Disclaimer

Figures

Figure 1
Figure 1. Species-variable inhibitor binding site of PfDHODH
A. Structure of the DHODH inhibitor 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) 1. B. Amino acid residues within 4.2 Å of the co-crystallized inhibitor 1 are shown. The inhibitor (pink) is displayed showing the Van der Waals surface, the FMN cofactor (yellow) and orotate (pink) are displayed as sticks. Residues in grey are conserved between PfDHODH and hDHODH, while residues in green are variable. The two amino acid residues that differ between PfDHODH and PbDHODH are indicated by *. The figure was generated using PyMol from the file 1TV5.pdb.
Figure 2
Figure 2. Plasma exposure of 2 and 3 after repeat dosing in mice
Control mice (designated C) were administered blank vehicle for 4 days, followed by a single oral dose of 2 (panel A) or 3 (panel B) at 50 mg/kg (n=3 mice per time point) on day 5. For the repeat dosing groups, an oral dose of 50 mg/kg was administered 1x daily using two schedules: a) compound was administered on days 3, 4 and 5 with vehicle administered on days 1 and 2, or b) compound was administered on days 1–5. Plasma concentrations were measured at 30 and 240 min after the day 5 dosing for all groups.
Figure 3
Figure 3. Comparison of the series activity on PfDHODH vs P. falciparum whole cell assays
The log of the PfDHODH IC50 data are plotted versus the log of the P. falciparum EC50 data (in micromolar). The plotted data include compounds 2, 3, 12, 13, 16, 18, 21, 24, 27, 36, 40, 42 and 47 described in Table 1 and those previously reported from the series (compounds 8–12 and 14–17 from 22). Compounds for which solubility limits prevented the quantitative determination of either the IC50/EC50 have been left off the plot. Data were fitted by linear regression analysis where r2 = 0.73, slope = 0.78 ± 0.087.
Figure 4
Figure 4. In vivo mouse efficacy studies for compound 21
A. Plasma concentrations after a single oral dose (20 mg/kg or 50 mg/kg) of 21 in mice. Peak plasma concentrations were 7.9 and 27.6 µM (2.3 and 8.1 µg/mL) and the apparent half-life was 1.8 h and 3 h at 20 mg/kg and 50 mg/kg, respectively. B. Efficacy in the standard P. berghei mouse model. Mice were infected with parasites on day 0, and compound 21 dosing began on day 1 after the presence of parasites was established. Dosing was by the oral route at either 50 mg/kg q.d. for 4 days (squares, solid lines) or 50 mg/kg b.i.d. for 4 days (triangles, solid lines) (days 1–4). No drug control data for each group is displayed with a broken line.
Scheme 1
Scheme 1
Synthetic strategy for the compounds 8–47a. a Reagents and conditions:(i) CH3COCH2CO2C2H5, AcOH, 3.5 h, reflux, 55%.; (ii) POCI3, 45 min., reflux, 58%.; (iii) Ar-NH2, EtOH, 2–30 h, room temp., 80–87%.
See this image and copyright information in PMC

References

    1. Greenwood BM, Fidock DA, Kyle DE, Kappe SHI, Alonso PL, Collins FH, Duffy PE. Malaria: progress, perils, and prospects for eradication. J. Clin. Invest. 2008;118:1266–1276. - PMC - PubMed
    1. Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, Hay SI, Snow RW. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med. 2008;5:e38. - VSports注册入口 - PMC - PubMed
    1. White NJ. Antimalarial drug resistance. J Clin Invest. 2004;113:1084–1092. - PMC (VSports app下载) - PubMed
    1. Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. N Engl J Med. 2008;358:1829–1836. - PubMed
    1. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DMA, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002;419:498–511. - PMC (V体育官网) - PubMed

Publication types

MeSH terms

Substances